{
  "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
  "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204",
  "summary": [
    {
      "type": "bullet",
      "text": "**KEY FINDING**: PROs predict all-cause mortality and HF-related hospitalization in ATTR-CM."
    },
    {
      "type": "bullet",
      "text": "**TACTICAL WIN [SHIP NOW]**: Prioritize tools that integrate KCCQ and EQ-5D-5 L for early trial inclusion."
    },
    {
      "type": "bullet",
      "text": "**MARKET SIGNAL [ðŸ”´ URGENT]**: FDA's growing emphasis on PROs may accelerate approval timelines."
    },
    {
      "type": "bullet",
      "text": "**CONCERN**: Self-selection bias could inflate perceived PRO benefits in ATTR-CM trials."
    }
  ],
  "model": "granite4:tiny-h"
}